Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 3 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10947216

    Amide compounds and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  2. US 10941134

    AMPK-activating heterocyclic compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  3. US 10941140

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  4. US 10941135

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  5. US 10889562

    Prodrugs of Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted
  6. US 10858335

    2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  7. US 10851093

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  8. US 10844040

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  9. US 10828301

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted
  10. US 10822337

    TGF-β inhibitorC

    Rigel Pharmaceuticals, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  11. US 10815206

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  12. US 10792282

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  13. US 10774066

    Prodrugs of NRF2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  14. US 10774076

    Benzazole compounds and methods for making and using the compounds

    Rigel Pharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  15. US 10759855

    Antigen binding molecules to TIGIT

    Rigel Pharmaceuticals, Inc. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  16. US 10710983

    2,4-diamino-pyrimidine compounds and method for making and using the compounds

    Rigel Pharmaceuticals, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted
  17. US 10709703

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted
  18. US 10696693

    Fused imidazole derivatives as TGF-beta inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted
  19. US 10682350

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  20. US 10647697

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted May 12, 2020 · Expires May 7, 2040

    granted
  21. US 10590121

    Kinase inhibitors and methods for making and using

    Rigel Pharmaceuticals, Inc. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted
  22. US 10577381

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  23. US 10556891

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted
  24. US 10556881

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted